About Ambit Biosciences
Ambit Biosciences is a company based in San Diego (United States) founded in 2000 was acquired by Daiichi Sankyo in September 2014.. Ambit Biosciences has raised $162.73 million across 6 funding rounds from investors including Daiichi Sankyo, Orbimed and Gimv. The company has 55 employees as of December 31, 2015. Ambit Biosciences offers products and services including Quizartinib, AC410, CSF1R Program, and CEP-32496. Ambit Biosciences operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter San Diego, United States
- Employees 55 as on 31 Dec, 2015
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ambit Biosciences Corporation
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$162.73 M (USD)
in 6 rounds
-
Latest Funding Round
$50 M (USD), Series E
Nov 07, 2012
-
Investors
Daiichi Sankyo
& 14 more
-
Employee Count
55
as on Dec 31, 2015
-
Acquired by
Daiichi Sankyo
(Sep 28, 2014)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ambit Biosciences
Ambit Biosciences offers a comprehensive portfolio of products and services, including Quizartinib, AC410, CSF1R Program, and CEP-32496. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
FLT3 inhibitor for treating acute myeloid leukemia in oncology.
JAK2 inhibitor targeting autoimmune and inflammatory conditions.
CSF1R inhibitor for oncology and inflammatory disease applications.
BRAF kinase inhibitor for cancer therapy development.
Funding Insights of Ambit Biosciences
Ambit Biosciences has successfully raised a total of $162.73M across 6 strategic funding rounds. The most recent funding activity was a Series E round of $50 million completed in November 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series E — $50.0M
-
First Round
First Round
(14 Nov 2007)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2012 | Amount | Series E - Ambit Biosciences | Valuation | Orbimed , Aisling Capital |
|
| Jun, 2011 | Amount | Series D - Ambit Biosciences | Valuation | Apposite Capital | |
| Oct, 2010 | Amount | Series D - Ambit Biosciences | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ambit Biosciences
Ambit Biosciences has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Daiichi Sankyo, Orbimed and Gimv. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
PE firm investing in the US
|
Founded Year | Domain | Location | |
|
Healthcare impact investments are managed by Apposite Capital.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ambit Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ambit Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ambit Biosciences Comparisons
Competitors of Ambit Biosciences
Ambit Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Ambit Biosciences
When was Ambit Biosciences founded?
Ambit Biosciences was founded in 2000 and raised its 1st funding round 7 years after it was founded.
Where is Ambit Biosciences located?
Ambit Biosciences is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is Ambit Biosciences a funded company?
Ambit Biosciences is a funded company, having raised a total of $162.73M across 6 funding rounds to date. The company's 1st funding round was a Series D of $15M, raised on Nov 14, 2007.
How many employees does Ambit Biosciences have?
As of Dec 31, 2015, the latest employee count at Ambit Biosciences is 55.
What does Ambit Biosciences do?
Ambit Biosciences was founded in 2000 in San Diego, United States, focusing on the biotechnology sector. Kinase inhibitors were developed by the company for treating cancer and immune disorders. The lead product, quizartinib, an FLT3 inhibitor, advanced to phase III clinical trials for acute myeloid leukemia. Operations centered on drug discovery and development until the acquisition by Daiichi Sankyo in 2014.
Who are the top competitors of Ambit Biosciences?
Ambit Biosciences's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Ambit Biosciences offer?
Ambit Biosciences offers Quizartinib, AC410, CSF1R Program, and CEP-32496.
Who are Ambit Biosciences's investors?
Ambit Biosciences has 15 investors. Key investors include Daiichi Sankyo, Orbimed, Gimv, Horizon Tech Finance, and Aisling Capital.